Serotonin syndrome - Presentation of 2 cases and review of the literature

被引:197
作者
Mason, PJ [1 ]
Morris, VA [1 ]
Balcezak, TJ [1 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Med Consult Serv, New Haven, CT 06510 USA
关键词
D O I
10.1097/00005792-200007000-00001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serotonin syndrome is an underreported complication of pharmacotherapy that has been relatively ignored in the medical literature. We discuss 2 recent cases seen at our institution and 39 cases described in the English-language literature since 1995. We found that patients with serotonin syndrome most often (74.3%) presented within 24 hours of medication initiation, overdose, or change in dosage. The most common presenting symptoms and signs were confusion, agitation, diaphoresis, tachycardia, myoclonus, and hyperreflexia. The prevalences of hypertension, coma/unresponsiveness, seizures, and death were not as prominent in our study as previously reported, perhaps reflecting earlier recognition and intervention. The most common therapeutic intervention was supportive care alone (48% of patients). The use of 5-hydroxytryptamine (5-HT) antagonists such as cyproheptadine, however, has become more common and might reduce the duration of symptoms. Only 1 death occurred, and most patients (57.5%) had complete resolution of their symptoms within 24 hours of presentation. The increased use of serotonergic agents (alone and in combination) across multiple medical disciplines presents the possibility that the prevalence and clinical significance of this condition will rise in the future. Internists will need to be increasingly aware of and prepared for this pharmacologic complication. Prevention, early recognition of the clinical presentation, identification and removal of the offending agents, supportive care, and specific pharmacologic therapy are all important to the successful management of serotonin syndrome.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 52 条
[1]   SEROTONIN SYNDROME FROM FLUVOXAMINE AND BUSPIRONE [J].
BAEZ, M ;
MALCOLM, D .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1995, 40 (07) :428-429
[2]   SEROTONIN SYNDROME [J].
BODNER, RA ;
LYNCH, T ;
LEWIS, L ;
KAHN, D .
NEUROLOGY, 1995, 45 (02) :219-223
[3]  
Brazelton T, 1997, ANN EMERG MED, V30, P550
[4]  
Callaway JC, 1998, J PSYCHOACTIVE DRUGS, V30, P367
[5]   EFFECTS OF PUTATIVE 5-HYDROXYTRYPTAMINE ANTAGONISTS ON BEHAVIOR PRODUCED BY ADMINISTRATION OF TRANYLCYPROMINE AND L-TRYPTOPHAN OR TRANYLCYPROMINE AND L-DOPA TO RATS [J].
DEAKIN, JFW ;
GREEN, AR .
BRITISH JOURNAL OF PHARMACOLOGY, 1978, 64 (02) :201-209
[6]   Fatal serotonin syndrome caused by moclobemide-clomipramine overdose [J].
Ferrer-Dufol, A ;
Perez-Aradros, C ;
Murillo, EC ;
Marques-Alamo, JM .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1998, 36 (1-2) :31-32
[8]   Serotonin syndrome due to an overdose of moclobemide and clomipramine - A potentially life-threatening association [J].
Francois, B ;
Marquet, P ;
Desachy, A ;
Roustan, J ;
Lachatre, G ;
Gastinne, H .
INTENSIVE CARE MEDICINE, 1997, 23 (01) :122-124
[9]   Possible serotonin syndrome with trazodone addition to fluoxetine [J].
George, TP ;
Godleski, LS .
BIOLOGICAL PSYCHIATRY, 1996, 39 (05) :384-385
[10]   Serotonin syndrome: history and risk [J].
Gillman, PK .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1998, 12 (05) :482-491